Simply Wall St
3 min read
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Bristol Myers Squibb (NYSE:BMY) has entered a partnership with Evinova to use AI tools in clinical trial design and execution.
The company is focusing this collaboration on speeding up and refining development across its drug pipeline.
Analysts have recently updated success probabilities for several key pipeline therapies, reflecting closer attention to upcoming programs.
Management has highlighted 2026 as a year with multiple pivotal clinical data readouts expected across major candidates.
Bristol Myers Squibb is a large biopharmaceutical company with a focus on oncology, immunology, cardiovascular and other specialty therapies. The new AI partnership with Evinova is closely aligned with its business model, which relies on bringing complex, high value medicines through clinical testing and to market. For investors, this relates directly to how efficiently NYSE:BMY can progress its research pipeline.
Looking ahead, the emphasis on 2026 as a data heavy year highlights how much of the current narrative is tied to clinical milestones rather than near term earnings changes. As AI tools begin to influence trial design and management, investors may want to monitor how quickly NYSE:BMY advances studies and updates guidance on key programs. The combination of AI driven development and a concentrated group of pivotal readouts could influence how the market assesses the company’s long term profile.
Stay updated on the most important news stories for Bristol-Myers Squibb by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bristol-Myers Squibb.
NYSE:BMY Earnings & Revenue Growth as at Feb 2026
How Bristol-Myers Squibb stacks up against its biggest competitors
⚖️ Price vs Analyst Target: At US$60.77 versus a consensus target of US$59.91, the share price is roughly 1% above analyst expectations, which is well within the 10% band.
✅ Simply Wall St Valuation: Simply Wall St’s model suggests the shares are trading at about 56.3% below estimated fair value, flagged as undervalued.
✅ Recent Momentum: The 30 day return of roughly 8.8% points to positive short term price momentum as the pipeline story gains attention.
Check out Simply Wall St’s in depth valuation analysis for Bristol-Myers Squibb.
📊 The Evinova AI partnership and higher analyst confidence in key therapies put more weight on execution quality in clinical development.
📊 Keep an eye on 2026 pivotal readouts, the P/E versus the industry average of about 21.2, and how R&D news lines up with any revisions to earnings forecasts.
⚠️ Analysts currently expect earnings to decline by an average of 2.4% per year over the next 3 years, so R&D wins need to offset that pressure.
For the full picture including more risks and rewards, check out the complete Bristol-Myers Squibb analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BMY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Terms and Privacy Policy